Large-scale testing (Phase 3)Ended earlyNCT00112281
What this trial is testing
The Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack
Who this might be right for
Shock, Cardiogenic
Arginox Pharmaceuticals 658